Aerospace and defense company BWX (NYSE:BWXT) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 26.1% year on year to $860.2 million. Its non-GAAP profit of $1.12 per share was 21% above analysts’ consensus estimates.
Is now the time to buy BWXT? Find out in our full research report (it’s free for active Edge members).
BWX (BWXT) Q1 CY2026 Highlights:
- Revenue: $860.2 million vs analyst estimates of $837.3 million (26.1% year-on-year growth, 2.7% beat)
- Adjusted EPS: $1.12 vs analyst estimates of $0.93 (21% beat)
- Adjusted EBITDA: $148 million vs analyst estimates of $134.8 million (17.2% margin, 9.8% beat)
- Management raised its full-year Adjusted EPS guidance to $4.68 at the midpoint, a 1.1% increase
- EBITDA guidance for the full year is $657.5 million at the midpoint, above analyst estimates of $651.3 million
- Operating Margin: 12.4%, down from 14.2% in the same quarter last year
- Backlog: $8.65 billion at quarter end, up 77.3% year on year
- Market Capitalization: $19.85 billion
StockStory’s Take
BWX’s first quarter results for 2026 exceeded Wall Street’s expectations for both revenue and non-GAAP earnings, but the market reaction was notably negative. Management attributed the performance to higher throughput, strong operational execution, and robust demand in both government and commercial segments. CEO Rex Geveden pointed to “improved throughput, favorable pacing of work, and exceptional operational execution” as major contributors. The company also highlighted a significant year-over-year increase in backlog, which management believes offers clear visibility for future growth.
Looking ahead, BWX’s revised guidance hinges on increased investment in U.S. nuclear manufacturing capacity and continued strength in the commercial and government nuclear markets. Management raised non-GAAP earnings expectations for the year, citing ongoing expansion projects and anticipated contributions from new acquisitions. CFO Michael Fitzgerald emphasized that “expansion of U.S. commercial nuclear manufacturing capacity and advanced nuclear and fuel capabilities” will remain core focus areas, while CEO Rex Geveden noted the company is “betting on the race” across the nuclear value chain to capture long-term opportunities.
Key Insights from Management’s Remarks
Management attributed first quarter outperformance to operational execution, capacity expansion, and a surge in nuclear sector demand, particularly for commercial nuclear solutions and government contracts.
- Commercial segment acceleration: Organic revenue in commercial operations surged, driven by strong demand for nuclear power components and medical products. Management noted that increased throughput on large projects, such as the Pickering life extension, and a solid contribution from the Kinectrics acquisition led to performance ahead of expectations.
- Backlog expansion: The company ended the quarter with a 77% year-over-year increase in backlog, supported by robust government bookings and sustained commercial interest. Management highlighted that this backlog provides improved visibility and underpins confidence in future revenue streams.
- U.S. manufacturing footprint buildout: BWX announced the acquisition of Precision Components Group (PCG), a manufacturer serving naval and commercial nuclear markets. This move marks the first step in establishing a domestic U.S. manufacturing presence, with plans for further expansion at the Mount Vernon site to support both current and anticipated demand for large-scale nuclear components.
- Operational initiatives: The company’s Driving Performance Excellence (DPX) program, aimed at enterprise-wide process optimization, was credited for improved throughput and reduced lead times. Management sees these initiatives as critical to meeting growing customer demand and enhancing profitability.
- Government program momentum: In government operations, growth in special materials and naval propulsion offset lower volumes in microreactors. Strong bookings, including new contracts for naval reactors and long-lead procurement, contributed to a substantial increase in government segment backlog.
Drivers of Future Performance
BWX expects continued growth this year, driven by capacity expansion, new commercial and government projects, and ongoing investments in advanced nuclear technologies.
- Capacity expansion and localization: Management believes that the development of new U.S.-based nuclear manufacturing facilities, including the integration of PCG and a planned greenfield plant, will be crucial in capturing both commercial and government opportunities. Localized supply chains are expected to become a competitive advantage, particularly as customers increasingly prefer domestic suppliers for nuclear projects.
- Advanced nuclear and medical growth: The company is investing in advanced nuclear fuel and reactor technologies—such as TRISO fuel and microreactors—as well as expanding its medical isotope production. Management highlighted strong demand for both established and new therapeutic products, positioning BWX to benefit from trends in defense, energy, and healthcare sectors.
- Execution risks and capital discipline: While pursuing aggressive growth and expansion, management acknowledged potential risks in project delivery and capital spending. CFO Michael Fitzgerald stated that capital expenditures may rise above 6% of sales if greenfield projects proceed, but emphasized a focus on maintaining financial discipline and not returning to historically higher levels of capital intensity.
Catalysts in Upcoming Quarters
Over the next few quarters, the StockStory team will closely monitor (1) the pace of U.S. manufacturing expansion, including progress on the Mount Vernon facility and the integration of PCG, (2) the conversion of backlog into revenue, especially in commercial and government nuclear projects, and (3) continued growth in advanced nuclear fuel and medical isotope businesses. Further signs of customer preference for localized nuclear supply chains and new contract wins will also be key indicators.
BWX currently trades at $207.88, down from $216.68 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it’s free).
High Quality Stocks for All Market Conditions
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum - both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks - FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.